drugset / Trial / NCT05027425
Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
NaSingle-groupOpen-labelTreatment
Summary
Immunotherapy can safely downstage patients and achieve durable systemic disease control to improve clinical outcomes in HCC patients undergoing liver transplant.
Timeline
- Start
- 2021-12-07
- Primary completion
- 2024-11-07
- Completion
- 2024-11-07
Outcome
Outcome not reported
Stopped (Enrollment): “The study is closing due to low enrollment and feasibility of the study.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | Tremelimumab | Monoclonal antibody | 300 mg | Intravenous |